Reviewing Amneal Pharmaceuticals (NASDAQ:AMRX) and Annovis Bio (NYSE:ANVS)

Amneal Pharmaceuticals (NASDAQ:AMRX) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and Annovis Bio”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$2.39 billion	1.09	-$83.99 million	($0.62)	-13.55
Annovis Bio	N/A	N/A	-$56.20 million	($5.75)	-1.72

Annovis Bio has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amneal Pharmaceuticals and Annovis Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	-6.72%	1,235.03%	4.64%
Annovis Bio	N/A	-876.22%	-374.65%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Amneal Pharmaceuticals and Annovis Bio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0	1	4	0	2.80
Annovis Bio	0	1	5	1	3.00

Amneal Pharmaceuticals presently has a consensus price target of $9.40, suggesting a potential upside of 11.90%. Annovis Bio has a consensus price target of $32.17, suggesting a potential upside of 225.90%. Given Annovis Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Amneal Pharmaceuticals.

Insider and Institutional Ownership

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 38.3% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Amneal Pharmaceuticals has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.72, meaning that its share price is 72% more volatile than the S&P 500.

Summary

Annovis Bio beats Amneal Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

About Annovis Bio

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.